Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx DRUG PRODUCER PRICES RISE 7.5% IN NINE MONTHS

Executive Summary

Rx DRUG PRODUCER PRICES RISE 7.5% IN NINE MONTHS of 1989 and have climbed 7.9% for the 12-month period from September 1988, according to the Labor Department Bureau of Labor Statistics' producer price index data released Oct. 12. Prescription drug prices at the manufacturer level climbed 2.5% in the quarter from July through September after inching ahead 0.3% in the second quarter, which historically is a period of price moderation. The rate of inflation for drug prices was significantly less in a one-month comparison with the inflation rate for finished goods, but much greater for the first nine months of the year. The PPI for all finished goods climbed 0.9% in September, while drug prices declined 0.7%. Through the nine months of 1989, the PPI for finished goods is ahead 3.2%. CNS stimulants/anti-obesity preparations led the increase in the PPI for prescription drugs with a price rise of 36.2%. for the nine months. The class was one of 10 drug categories where producer prices were up more than 10% for the nine-month period. For the third quarter, CNS stimulants/anti-obesity preps also experienced the highest rate of inflation among prescription drugs, increasing 10.9%. Hormones were the only class besides CNS stimulants/anti-obesity drugs where manufacturer-level prices pulled ahead more than 20%; the PPI for hormone drug products rose 23.3% through the nine months and 17.6% in the quarter. Joining the 10%-plus price rise ranks for the period January through September were: anti-arthritics; vasodilators; cough and cold preps; nasal decongestants; acne preps; psychotherapeutics; tranquilizers as a whole and minor tranquilizers. While the third quarter saw four drug categories with some inflation moderation, only two drug products had declines in their PPI level in the nine-month period. So far this year, the producer-level prices for anti-arthritics and broad and medium spectrum antibiotics are down 4.5% and 2.4%, respectively. Quarterly lessening of their price inflation was greater, with PPI declines of 7.9% and 3%, respectively. Other prescription drugs bucking the 2.5% overall inflationary trend for the quarter were major tranquilizers (down 0.3%) and manufacturer prices for adult multivitamins, which remained unchanged. The PPI for all OTC drugs increased 3.7% in the first nine months of 1989. Following a 3.1% rise through the first half, the quarterly PPI dropped 0.6%. Acne preps is the category with the greatest pricing flexibility among OTC products so far this year; the category was up 7%.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel